AXIM Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 15, 2022 at 03:52 am IST
Share
AXIM Biotechnologies, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 0.001314 million compared to USD 0.008127 million a year ago. Net loss was USD 2.03 million compared to USD 3.29 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.03 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.03 a year ago. Basic loss per share was USD 0.01 compared to USD 0.03 a year ago. Diluted loss per share was USD 0.01 compared to USD 0.03 a year ago.
For the nine months, sales was USD 0.001314 million compared to USD 0.055651 million a year ago. Net loss was USD 5.34 million compared to USD 7.98 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.06 a year ago. Diluted loss per share from continuing operations was USD 0.04 compared to USD 0.06 a year ago. Basic loss per share was USD 0.034 compared to USD 0.06 a year ago. Diluted loss per share was USD 0.034 compared to USD 0.06 a year ago.
Axim Biotechnologies, Inc. is an international healthcare diagnostic solutions development company. The Company is focused on improving the landscape for the diagnosis of ophthalmological conditions such as dry eye disease (DED) through rapid diagnostic tests. It has developed and commercialized two highly specialized point-of-care (POC) diagnostic tests, Ocular Immunoglobulin E (IgE) test and Lactoferrin test, which are designed specifically to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient DED and non-specific allergic conjunctivitis. In addition, it is also engaged in the development of a quantitative tear MMP-9 test to measure the intensity of inflammation affecting dry eye patients. It has also developed proprietary assays for the detection of QSOX1-L in patients undergoing cancer treatment. Its products also include SARS-CoV-2 neutralizing antibody tests and a fentanyl neutralizing antibody test.